Amsacrine (amsa) is a topoisomerase II inhibitor used in oncology as a chemotherapeutic agent, primarily for the treatment of acute leukemias (particularly acute myeloid leukemia, AML). It works by intercalating DNA and stabilizing the topoisomerase II-DNA complex, leading to DNA breaks and apoptosis.
Key Points for Oncology Pharmacists:
- Indications: Relapsed/refractory AML (less commonly ALL).
- Administration: IV infusion (typically over 60–90 minutes).
- Toxicities: Myelosuppression (dose-limiting), cardiotoxicity (QT prolongation, arrhythmias), hepatotoxicity, mucositis.
- Monitoring: ECG (QT interval), LFTs, CBC, electrolytes (K⁺/Mg²⁺).
- Drug Interactions: CYP3A4 substrates/inhibitors (metabolized via liver).
Amsacrine is rarely used today due to newer agents but remains an option in certain protocols.
Would you like details on dosing or specific protocols?
Synonyms
Amsa